타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Blenrep (belantamab mafodotin) |
Overview Company | GSK |
Overview Modality | ADC |
Overview Target | BCMA |
Overview Indication | Multiple myeloma |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | BCMA-targeted ADC with ocular AEs |
Positioning Known limitation | bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs) |
Technology Payload | MMAF |
Technology Linker | Non-cleavable |
MoA Mechanism | Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death. |
MoA Biomarker | BCMA expression on myeloma cells. |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Safety signal | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Blenrep (belantamab mafodotin) |
Overview Company | GSK |
Overview Modality | ADC |
Overview Target | BCMA |
Overview Indication | Multiple myeloma |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | BCMA-targeted ADC with ocular AEs |
Positioning Known limitation | bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs) |
Technology Payload | MMAF |
Technology Linker | Non-cleavable |
MoA Mechanism | Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death. |
MoA Biomarker | BCMA expression on myeloma cells. |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Safety signal | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교